Akero Therapeutics

Acquired

Akero Therapeutics is a life sciences company in South San Francisco, United States, founded in 2017. It has raised $135.0M across 2 rounds, most recently a $70.0M Series B in December 2018.

EFX for MASH | Metabolic Disease | Home

Employees
11–50
Founded
2017
Total Funding
$135.0M
Last Round
$70.0M Series BDec 2018
Rounds
2
Acquisition Date
Jan 2025

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds and 2 investors for this company. The full record is or through the API.

About

Akero Therapeutics is a clinical-stage biopharmaceutical company founded in 2017 to develop transformational treatments for patients with metabolic dysfunction-associated steatohepatitis (MASH) and other serious metabolic diseases. Its lead candidate, efruxifermin (EFX), advanced through Phase 3 trials before Novo Nordisk acquired Akero in 2025 to expand access to the therapy. The company is headquartered in South San Francisco, California.

Summary

It lists 11–50 employees. It has raised $135.0M in total across 2 rounds, most recently a $70.0M Series B round in Dec 2018. Investors include Novo Nordisk and Apple.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Data from Indexed.vcUpdated
AcquisitionOct 2025

Sign up to see all 5 events

Funding: Series A through Series B. Amounts, valuations, and investors where available.

Investors

Similar Companies

Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026
Isomorphic Labs

AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...

London, United Kingdom201–500Artificial Intelligence, Biotech
Series CTotal funding$2.6BNov 2026
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Calico

Calico researches human aging using advanced technologies and model systems, applying that knowle...

South San Francisco, United States201–500Biotech, Healthcare
Corporate RoundTotal funding$2.3BJun 2018
PHC

PHC is a leading provider of diabetes monitoring systems, specialized laboratory equipment, and c...

Minato, Japan5001–10000Healthcare, Life Sciences
Private EquityTotal funding$1.9BMar 2021

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Akero Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/akero"><img src="https://indexed.vc/api/badge/company/akero" alt="Akero Therapeutics on Indexed.vc" width="260" height="76" /></a>